GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (FRA:76X0) » Definitions » Cash Flow from Others

SomaLogic (FRA:76X0) Cash Flow from Others : €-5.49 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic Cash Flow from Others?

SomaLogic's cash flow from others for the three months ended in Sep. 2023 was €-1.46 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Sep. 2023 was €-5.49 Mil.


SomaLogic Cash Flow from Others Historical Data

The historical data trend for SomaLogic's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic Cash Flow from Others Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
Cash Flow from Others
12.62 9.28 -63.15

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.05 -2.20 -1.98 0.14 -1.46

SomaLogic Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.49 Mil.

SomaLogic Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of SomaLogic's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


SomaLogic (FRA:76X0) Business Description

Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.

SomaLogic (FRA:76X0) Headlines

No Headlines